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Biases of antimicrobial use (AMU) reporting systems pose a challenge to monitoring
of AMU. Our study aimed to cross-compare three data sources of AMU in Swedish
dairy herds to provide an account of the validity of AMU reports. We studied AMU
differences between two production systems, to investigate how the reporting system
affected this comparison. On-farm quantification of AMU via a manual collection of
empty drug containers (BIN) took place in organic (n = 30) and conventional (n =
30) dairy herds during two periods between February 2016 and March 2017. A data
extract mirroring these periods was obtained from two linked datasets that contain
AMU data as reported by the prescribing veterinarians. These included data from the
Swedish Board of Agriculture system (SBA) and Växa milk recording system (VXA).
Using the European Medicines Agency technical units, the total number of defined daily
doses (DDDvet), and defined course doses (DCDvet) per animal/year were calculated for
each herd/period/dataset. Descriptive statistics and Bland–Altman plots were used to
evaluate the agreement and systematic bias between the datasets. Mixed models for
repeated measures were used to assess AMU differences between production systems.
We found consistent numerical differences for the calculated AMU metrics, with BIN
presenting higher usage compared to the SBA and VXA. This was driven by a disparity
in intramammary tubes (IMt) which appear to be underreported in the national datasets.
A statistically significant interaction (BIN dataset) between the production system and
drug administration form was found, where AMU for injectable and lactating cow IMt
drug forms differed by the production system, but no difference was found for dry-cow
IMt. We conclude that calculating AMU using DDDvet and DCDvet metrics at a herd level
based on Swedish national datasets is useful, with the caveat of IMt potentially being
misrepresented. The BIN method offers an alternative to monitoring AMU, but scaling up
requires considerations. The lower disease caseload in organic herds partly explains the
lower AMU in particular drug forms. The fact that organic and conventional herds’ had
equally low AMU for dry-cow IMt, coupled with mismatches in IMt report across herds
indicated an area of further research.
Keywords: BIN method, national surveillance systems, farm level, DDDvet metric, DCDvet metric, AMU
Olmos Antillón et al. Antibiotic Use in Swedish Dairy Farms
INTRODUCTION
Antimicrobial resistance (AMR) is a global issue, and the
current pattern and reduction in its harmful consequences to
the biosphere’s health (1, 2) require concerted actions from the
human, animal, agricultural, and environmental sectors (3). A
key measure for AMR mitigation is reducing antimicrobial use
(AMU), especially “Critically Important Antimicrobials” (CIAs)
for human health (4–6). The livestock industry is predicted to
be responsible for 70% of the global AMU by 2030 (2, 7) and
the possible relationship between AMU in animal production,
and the development of AMR has been highlighted (8). Despite
the association between AMR in livestock and humans, there is
uncertainty about its magnitude (9–11).
Measuring AMU is fundamental for monitoring and
reduction of AMU. Key indicators for understanding the
patterns include (a) monitoring trends over time; (b)
comparisons between different populations (e.g., types of
production, species, or countries); (c) benchmarking; and (d)
study of associations between AMU and AMR (12). To date,
no standardised AMU measurement fulfils all these objectives.
Thus, suitable measurement(s) must be determined based on a
trade-off between the set goals and data at hand. Data resolution,
comprehensiveness, and stability over time are important for
the assessment of exposure and comparison of AMU within and
between populations (12, 13).
All the practicalities around collection and reporting,
regardless of the chosen resolution (e.g., animal, herd, or country
level), have a high impact on AMU measurements. In turn, this
affects the transparency and comparability of figures obtained.
Despite this, only a few studies have addressed the qualitative and
quantitative biases of AMU reporting systems (12, 14–16).
In Sweden, AMU in animals is only allowed on veterinary
prescription, and veterinary drugs are sold exclusively through
registered pharmacies. Sweden has had a leading role in the
reduction of AMU, as well as the quantification and reporting
of AMU statistics in animals and humans via the Swedres-Svarm
reports (17). These reports are based on national sales data, which
are not always the same as the amount prescribed or used in
a country.
Although no recent effort has been made to evaluate AMU
at herd level in Swedish dairy herds (18), the tools to do so
are available through official records of veterinary treatments.
The “Djursjukdata DAWA” is owned by the Swedish Board of
Agriculture (in Swedish: Jordbruksverket). This is the oldest
data collection system for veterinary treatments in Sweden,
including antimicrobial use at herd level, initially compiled
via paper records and launched at a national level in 1984.
Currently, a computerised system covers all food-producing
animals and horses, although 30% of the data is still fed to
the system in paper format. Moreover, this system provides
health information to Växa, the biggest dairy Levy group in
Sweden that aims to monitor and improve the productivity,
health and welfare of Swedish dairy cows (19). Växa’s national
database thus opens the window to understanding AMU in
the context of detailed herd characteristics not available in the
DAWA system.
Based on the EU rules for organic farming, dairy herds
are expected to maintain a restrictive AMU (20). In practice,
these rules limit the number of treatments per animal/year, and
depending on the member state, might include the extension
of drug withdrawal periods or the promotion of alternative
medicines. Since conventional herds do not have to abide by
such rules, it is often assumed that AMU would be higher in
these herds. Although some studies have confirmed that organic
herds have a lower AMU than conventional herds (5, 21–25), this
research area remains unexplored in Sweden. The requirements
may also impact the role of prescribing veterinarians under
the two systems and, thus, also the AMU recordings. Hence, a
comparison between AMU in organic and conventional dairy
herds provides a case for AMU data evaluation.
This study aimed to provide a qualitative and quantitative
assessment of how data source affects AMU reports, including
treatment characteristics and characteristics of the population
treated and at risk within a herd. Additionally, we wanted
to quantify, describe, and compare the AMU in organic and
conventional Swedish dairy herds and explore if AMU recording
differs between the systems.
METHODOLOGY
Herd Enrolment
The study design adhered to the good scientific practice
guidelines set out by Swedish legislation and did not include
direct animal testing. Thus, no ethical evaluation or permit
was required for its execution. Suitable farms were invited to
participate through veterinarians, farmer’s organisations and
advisors. The farms were chosen to reflect the size and
distribution of dairy herds in Sweden. Each organic and
conventional farm was geographically matched. The overall aims
of the study were explained to the farmers who, when they agreed
to join, signed a form that approved the use of data from their
herds for research purposes within the context of this study. A
total of 60 farmers were enrolled in the project, 30 organic and 30
conventional dairy farms.
Data Collection
The AMU was assessed during two periods: February to May
2016 and November 2016 toMarch 2017 using three data sources
(see Figure 1). Two data sources are based on antimicrobial
prescription data [Växa Sverige (VXA) and Swedish Border of
Agriculture (SBA)] while the third one [empty drug containers
(BIN)] compiled data on actual AMU on farm.
On-Farm Collection of Empty Drug Containers (BIN)
The second author (KS) met with the owners and farm staff 1 day
before the start of the observation period. The methodology was
explained/reinforced, and labelled plastic bags were provided.
Staff were instructed to place discarded packaging (empty or
partially full: bottles, boxes of pills/boluses, empty infusion tubes
or other) of any drug used on-farm (administered by them
or a visiting veterinarian) into the plastic bags throughout the
observation period. The farm staff decided where to place the
bags to facilitate the collection on their respective farms. Bags
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FIGURE 1 | Flow diagram of methodology, dataset relationship, and data availability for antimicrobial use collection for a sample of 30 organic and 30 conventional
Swedish dairy herds across two observation periods and as reported by three different datasets.
were collected 1 day after the end of each observation period. Due
to travel logistics, not all farms were visited on the same day or
had the same length of the collection period.
Only herd owners who stated “having used drugs” and
had items in the bags/bins (n = 55 and n = 54 herds in
sample period 1 and 2, respectively) or those who stated “not
having used drugs” and had no items in the bins (n = 3 and
n = 5 herds in sample period 1 and 2, respectively) were
considered for each observation period. The contents of the
bags from each herd were tallied, and (1) anonymised herd
code and collection period, (2) drug commercial name, (3)
drug amount and unit, (4) drug concentration (e.g., mg/ml
or gr/unit), and (5) name of related active ingredients were
recorded into a Microsoft R© Excel (Microsoft Corporation,
Redmond, WA, USA) spreadsheet for further analysis. If drug
packages were not empty, only the amount used was noted. The
commercial names were linked to the corresponding code of
the Anatomical, Therapeutic, and Chemical Veterinary (ATCvet)
classification registered under the Swedish Pharmaceutical
Industry Association Service (Läkemedelsindustriföreningens
Service AB). This is publicly available in the online compendium
known as Pharmaceutical specialties in Sweden (www.fass.
se). If the commercial name/active ingredients were not
found/registered under this system, the ATCvet code was assigned
based on information retrieved from the European Head of
Medicines Agency (www.hma.eu).
Swedish Board of Agriculture Antimicrobial Use Data
Extract (SBA)
A data extract of the drugs used by the participating herds
comprising the two observation periods was requested from the
Swedish Board of Agriculture. Such information is contained
in one of the three main DAWA report sections. The reports
are submitted by state-employed veterinarians in the form of
text files from their computer program LINK, via the DAWA e-
service. Most private veterinarians also use a similar format with
<30% of them sending in physical practice journal forms.
The original extract had the following information: (1)
anonymised herd code, (2) diagnostic code, (3) drug commercial
name, (4) ATCvet code, (5) drug unit and amount used, (6) type of
treatment (single, group, or all animals), (7) number of animals
involved, and (8) treatment date.
The received data extract was screened for usability. The
following problems were found, and data records were corrected
or discarded as follows. Records with non-existent, incomplete,
or incoherent drug name or ATCvet codes were identified. If
such records had a recognisable drug name or a partial ATCvet
code, a complete code was assigned following the same procedure
as for the BIN dataset. Some records had no name or ATCvet
code, but instead, a note indicating “error of data transfer,” “drug
under license,” or “unknown product” was found. As no valid
assumptions could be made about the data entries (i.e., unknown
relation), such records were eliminated from further analysis.
Lastly, only records/events that took place during the individual
herd’s observation periods were kept for further investigation.
Växa Sverige Data Extract (VXA)
The second data extract of drug use came from Växa Sverige
(VXA), the Swedish dairy cattle association that provides on-
farm advice and milk recording services to their members. VXA
registers 2,003 herds (76% of all Swedish herds) comprising
220,131 animals (78% of all Swedish dairy cows) in their data
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control system (19, 26). The system captures animal-level events
based on their unique national animal identifier. Such events
include pedigree, birth/death, cow movements, calving events,
milk quantity and quality records, and disease events. An extract
of the pedigree, cattle movement, and sickness events was
obtained covering the two observation periods of all animals
related to the participating herds. Besides, summary statistics per
participating herd for the fiscal year October 2016 to September
2017 were also obtained from Växa Sverige.
The pedigree and cattle movement reports are actively
updated by on-farm staff, providing information about the actual
herd size and composition at the time of the two observation
periods. Moreover, the disease reports contained information
about drug use at the animal level. Such reports are generated
by pulling data from the SBA system, including the drug use,
through an active back-end communication interface between
the two systems. Additional but minimal input by farm staff can
happen, but without affecting drug usage information.
Data extracts were screened for usability and, when necessary,
edited. There were no errors found with the pedigree or cow
movement data. The animal age and number of days each animal
was active in the participating herds at each observation period
were calculated. Based on cow age, a new variable was created
that classifies animals as either (a) cows/bulls (adult animals
>730 days old), (b) heifer/steers (animals >365 ≤730 days old),
and(c) young/calves (<365 days old). The common information
allowed calculating the individual herds’ population at risk
of receiving antimicrobial treatment during each observation
period so that AMU estimates could be adjusted for herd size and
age differences.
Disease data provided the following information at animal
level: drug/treatment product as a code, treatment date, diagnosis
∑n
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code, and amount used. The treatment code was cross-matched
with a translation code list that provides information about the
commercial drug name, and ATCvet code comparable to the
SBA dataset. Some data entries matched no name or ATCvet
code but had notes indicating “drug under license” or “unknown
product.” Such entries (i.e., unknown relation) were removed
from further analysis. Lastly, only records/events that mirrored
the individual on-farm BIN observation periods were kept for
further investigation.
Estimation of Herd-Level AMU
A full list of commercial drug names and linked ATCvet codes
identified across the three datasets was compiled. The list
contained only ATCvet codes mentioned in the European
Medicines Agency (EMA) protocol (27) for AMU quantification.
These ATCvet code groups include (A) Intestinal/oral (O)
use: QA07AA, QA07AB; (B) Intrauterine (IU) use: QG01AA,
QG01AE, QG01BA, QG01BE, QG51AA, QG51AQ; (C)
Systemic/Injectable (IN) use: QJ01; (D) Intramammary tubes
(IMt): QJ51; and (E) Antiparasitic agents: QP51AG. The final
list had 16 individual ATCvet codes, representing 26 commercial
products, of which 38% were products with a combination of
drugs (i.e., products had two or more active ingredients in its
composition). We used this list to select records relevant for
AMU calculations from each dataset and the herd/dataset/period
AMUmetric calculations.
Animals of all ages were included in the AMU calculations.
The standardised live weight used in the EMA protocol is lower
than the national average in Swedish national statistics (19, 28).
Instead, it was decided to use the following standard weights.
Cows/bulls (i.e., adults animals) = 600 kg; heifers/steers (i.e.,
pubescent animals) = 300 kg; and calves (i.e., young animals)
= 100 kg, as these figures represent the Swedish national herd.
Production days were defined as the actual number of days an
animal was kept in the herd during the observation periods,
according to livestockmovement data in the VXA dataset extract.
The number of cow-years per herd was calculated using the total
number of cows’ production days per herd divided by 365.
Amounts of active antimicrobial substance were calculated by
multiplying the volume administered to the animals (usually in
ml) by the concentration of the active antimicrobial substance
(e.g., mg/ml) to give the total mass of active antimicrobial
substance in mg for each dataset. Then, the number of defined
daily doses (DDDvet) and defined course doses (DCDvet)
administered was calculated using theDDDvet andDCDvet values
assigned to the individual antimicrobial substances (based on
ATCvet code) and animal species by the European Medicines
Agency (29, 30). The number of defined daily doses per animal
and year (nDDDvet/animal/year), the number of defined course
doses per animal and year (nDCDvet/animal/year) for the
individual ATCvet code, and the summation of all codes by herd
were calculated following the formula as advised by the network
on quantification, benchmarking and reporting of AMU at farm
level (AACTING) (13) as follows:
where:
AIi = amount (in mg) of active ingredient i used in period P
i= 1, 2, . . . , n
# animal days in period P = # animals present daily during
P (days).
Standard weight= standard cow weight at treatment (in kg)
DDDveti = Defined Daily Dose of active ingredient i (in
mg/kg/day); to calculate the number of days under treatment
over the defined period. If DDDveti is replaced by DCDveti
(Defined Course Doses), then the average number of courses per
animal will be calculated.
DDDveti & DCDveti can also be expressed in terms of the
number of items (e.g., IMt, bolus or pills), in which case the
number of items used in period P will be used in the formula
instead of the amount of active ingredient. Lactating intra-
mammary tubes are dosed at the number of tubes/cow/day,
while dry cow tubes are dosed as “4/cow” as a single treatment,
and intrauterine products are one unit per cow. Thus, DCDveti
figures can be calculated for dry-cow intra-mammary tubes and
intrauterine products.
Similar calculations were done according to the
administration route for each drug formulation (i.e.,
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IN, O, lactation IMt, dry-cow IMt, and IU) and by the
classification of critically important antimicrobials (CIAs) set
by EMA/AMEG/2016 (5, 25, 31) at the time when data was
collected. The classification set by EMA is a categorisation of the
list of highest-priority CIAs (HP-CIAs) for humans set by the
World Health Organization (WHO) (6). The EMA classification
aims to consider and advise on the public health risk from the
use of antimicrobials in animals expressed by WHO (6, 32), but
balancing against the need to protect animal health—providing
a One Health context considering the needs of humans, animals,
and environment and at the same time these sectors as sources
of AMR (5, 31). The EMA/AMEG/2016 classification (5, 25)
includes three categories: (1) antimicrobials used in veterinary
medicine, where the risk for public health is estimated as low or
limited; (2) antimicrobials used in veterinary medicine where the
risk for public health is estimated higher; and (3) antimicrobials
not approved for use in veterinary medicine.
Statistical Analyses
All analyses were conducted in SAS/STAT 14.3 (SAS Institute
Inc., Cary NC, USA).
Descriptive Presentation of Herd Characteristics and
AMU Metrics
A descriptive analysis of the key herd characteristics (VXA
dataset) and AMU metrics as DDDvet and DCDvet/animal/year
(all datasets) by active ingredient was done by calculating
the mean, median, standard deviation, and interquartile range.
Similar descriptive analyses were done for the summation of
all ATCvet codes within the herd (i.e., total DDDvet/animal/year
and total DCDvet/animal/year) and the total split by drug
administration form or by CIAs.
AMU Dataset Agreement and Biases Analyses
Bland–Altman plots consisting of the mean between two datasets
[(Dataset A+Dataset B)/2] of the herd total DCDvet/animal/year
plotted against the difference between the two datasets (Dataset
B–Dataset A) were constructed. The mean difference d between
dataset A and B represents the bias or lack of agreement
between datasets. The standard deviation of the difference d
represents the variability of the differences and is used to calculate
95% limits of agreement between the datasets. The 95% limits
of agreement represent the range within which 95% of the
observations (i.e., differences between dataset A and B) fall. They
are not confidence limits but function instead as a reference
interval (33). If the values of the differences within the range are
considered “clinically acceptable,” then the two methods could
be used interchangeably. The mean bias of the methods and the
SD of the bias were calculated, across the three datasets for the
herd total nDCDvet/animal/year and also split according to the
drug administration form. Ninety-five % limits of agreement,
calculated as the mean difference in dataset measures ±1.96∗SD,
were calculated and labelled on the Bland–Altman plots. A
horizontal line at y= 0was added to the plot to indicate the line of
equality upon which all points would lie if both methods yielded
the same results. Plots were then examined visually to identify
any patterns in the data. A second plot line was investigated.
This corresponded to the potential for bias that is not constant
across the range of values (proportional bias). For that, a linear
regressionmodel was fitted for each dataset, with the VXA or SBA
(Dataset A) dataset as the outcome variable and BIN (Dataset B)
dataset as the independent variable. The slope of the regression
line was used to evaluate the extent of systematic bias between
two particular datasets.
Analysis of AMU Differences Between Conventional
and Organic Dairy Herds
The association between the production system (conventional
vs. organic) and AMU was assessed using linear mixed models
(PROC MIXED), with the total number of DCDvet/animal/year
as the dependent variable and sampling period included as a
repeated effect within herd. This procedure was done for BIN
and VXA datasets separately. The residuals were tested for
normality both visually and analytically; when a variable was
not normally distributed, the Box–Cox methodology was used
to identify the most appropriate transformation. The analyses
were undertaken on the transformed, normally distributed data,
and back-transformed results are presented. Fixed effects tested
in the model were production system, observation period, drug
administration type (IN, lactating IMt, dry-cow IMt, O, and
IU), and the interaction between production type and drug
administration type. Compound symmetry was the selected
covariance structure used for all models. Factors significantly (P
< 0.05) associated with the dependent variable were retained in
the model.
RESULTS
Herd Characteristics and the Number of
Farms With Evidence of AMU
A summary of participating herds’ characteristics according to
their production system is presented in Table 1. Organic and
conventional farms had a similar herd size. However, organic
farms had lower milk production, mortality, lameness, and
clinical mastitis caseload, but higher bulk milk somatic cell count
than conventional farms.
The ratio of available data entries in SBA— “related” (i.e.,
ATCvet code linked to an antimicrobial formulation), “Not
related” (i.e., ATCvet code not linked to an antimicrobial
formulation), and with “Unknown relation” to AMU were 352
(27%): 839 (65%): 104 (8%) and 386 (24%): 1,130 (70%): 104 (6%)
for periods one and two, respectively. As for the VXA dataset, the
ratio of available data entries “related,” “Not related,” and with
“Unknown relation” to AMU were 385 (27%): 903 (62%): 159
(11%) and 399 (20%): 1,274 (65%): 289 (15%) for periods one and
two, respectively.
Corresponding records of AMU across datasets (i.e., at least
one entry of AMU per farm/period across all dataset) were found
in 77% of the farm/period entries (n = 47 farms P1, n = 45
farms P2). Only 2.5% of the farm/period entries had a note in
the BIN stating no AMU for the given period and no AMU
entry in the SBA and VXA datasets. This left 20.5% of the
farm/period entries with mismatching records of AMU across
datasets (Figure 1).
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TABLE 1 | Yearly herd characteristics in a sample of 26 organic and 25 conventional Swedish dairy herds.
Yearly herd characteristics (Reporting period
Oct. 2016–Sep. 2017)
Production system Mean Lower quartile Median Upper quartile
Average number cows/year Organic 103.8 66.3 73.1 133.2
Conventional 107.7 66.7 101.5 138.2
Energy corrected milk production (kg/cow/year) Organic 9,464 8,763 9,261 10,057
Conventional 10,545 10,132 10,743 11,055
*Bulk milk somatic cell count (1,000 cells/ml) Organic 282.8 234.0 300.5 327.0
Conventional 226.6 185.0 216.0 267.0
Mastitis (cases/100 cows/year) Organic 6.8 1.5 4.7 9.2
Conventional 10.1 3.7 9.0 10.6
On-farm mortality (cases/100 cows/year) Organic 4.1 2.8 4.1 5.2
Conventional 5.3 3.7 5.1 7.4
Lameness (cases/100 cows/year) Organic 2.6 0.0 1.0 4.1
Conventional 5.2 0.0 2.0 5.2
*An average estimate derived from the somatic cell count and milk yield of the individual cows at each monthly test-day.
At the time of data extraction; full data was available only for 51/60 herds involved in the study.
FIGURE 2 | Distribution of (A) herd total number of defined daily doses per animal/year (DDDvet/animal/year) and (B) herd total number of defined course doses
(DCDvet/animal/year) per animal/year in a sample of organic (n = 30) and conventional (n = 30) Swedish dairy herds reported across two periods and three datasets.
Box = the range between the 1st and 3rd quartiles; horizontal line = median; lower and upper whisker = interquartile range; dots = outliers. BIN, Bin collection
method records, n = 57 and n = 55 herds had reported use in P1 and P2, respectively. SBA, Swedish Board of Agriculture database, n = 51 and n = 53 herds had
reported use in P1 and P2, respectively. VXA, Växa Sverige database; n = 48 and n = 48 had reported use in P1 and P2, respectively.
Overall AMU Descriptive Statistics by
Dataset, Production Type, and Period
The DDDvet/animal/year and DCDvet/animal/year are presented
in Figure 2. At the same time, descriptive statistics are given
in the Supplementary Material along with details of AMU
concerning ATCvet codes. More herds with confirmed AMU
and higher within-herd AMU were observed in the BIN dataset
compared to the SBA and VXA datasets. Regardless of dataset,
organic herds had a numerically lower total AMU compared to
conventional farms.
Across datasets, injectable procaine benzylpenicillin
(QJ01CE09) was the main antibiotic prescribed of a list
of 16 drug formulations found. For all the drugs used,
there was a variation between prescription and the related
number of DCDvet/animal/year across datasets for each
period/production system. Further details can be found in the
Supplementary Material section of this paper.
Agreement and Biases Between Datasets:
Bland–Altman Plots and Regression
Analysis Results
The number of herd observations per dataset and the number of
corresponding observations between the datasets are shown in
Table 2. The number of herds reporting AMU for the primary
drug forms (IN and IMt) was higher for the BIN dataset than
SBA and VXA. The number of corresponding reports between
Frontiers in Veterinary Science | www.frontiersin.org 6 October 2020 | Volume 7 | Article 568881
Olmos Antillón et al. Antibiotic Use in Swedish Dairy Farms
TABLE 2 | Slope of the regression line comparing antimicrobial use (AMU) DCDvet/animal/year metric of three datasets, and bias, variability of the bias, and limits of




Comparison A vs. B *dataset aMean
bias








from 1 for the
slope
Herd × period with at
least one record of
AMU in Dataset A vs.
B, (n = concurrent
records found, % of
total herd observations
within category)
All forms BIN VXA −0.15 0.315 −0.766 0.469 0.16 0.011 108/96 (92, 77%)
SBA −0.08 0.337 −0.738 0.583 0.30 <0 0.0001 108/104 (98, 82%)
SBA VXA −0.07 0.258 −0.577 0.435 −0.13 0.003 104/96 (96, 81%)
Injectables/Parenteral BIN VXA −0.11 0.248 −0.598 0.374 0.18 <0.0001 107/96 (92, 81%)
SBA −0.08 0.239 −0.545 0.394 0.25 <0.0001 107/102 (96, 85%)
SBA VXA −0.04 0.128 −0.287 0.214 −0.08 0.017 102/96 (96, 85%)
Intramammary
lactation tubes
BIN VXA −0.01 0.092 −0.190 0.171 0.12 0.194 38/31 (23, 47%)
SBA 0.05 0.219 −0.379 0.479 0.73 <0.0001 38/38 (27, 55%)
SBA VXA −0.06 0.215 −0.481 0.362 −0.60 <0.0001 38/31 (31, 63%)
Intramammary
dry–cow tubes
BIN VXA −0.07 0.123 −0.315 0.169 0.06 0.759 54/12 (9, 15%)
SBA −0.05 0.137 −0.321 0.215 0.19 0.358 54/21 (14, 23%)
SBA VXA −0.02 0.058 −0.134 0.094 −0.08 0.227 21/12 (12, 20%)
aThe mean bias represents the difference between datasets as defined course doses/animal/year “B” —defined course doses/animal/year “A”. bThe LL (lower agreement limit) and UL
(upper agreement limit) represents the mean “bias” −1.96 × SD and the mean “bias” + 1.96 × SD, respectively.
*BIN, Bin collection method records; SBA, Swedish Board of Agriculture database; VXA, Växa Sverige database. Bold values indicate the P-value <0.05.
BIN and the other two datasets was low while between SBA
and VXA it was high. The number of corresponding reports
between datasets was high for IN formulations but low for IMt
formulations, especially for dry-cow IMt. Usage of O drugs was
found for two herds. The herds involved and time of observation
differed between BIN and the matching reports in the VXA and
SBA datasets. No usage of IU drugs was found in the BIN dataset
for any herd at any period, but records were found in SBA and
VXA for four herds in the first period.
The mean differences in the herd total DCDvet/animal/year
metric between datasets for the different drug forms, i.e., the
mean bias, the standard deviations of these differences, and the
limits of agreement, are shown in Table 2. Again, a greater AMU
was reported in the BIN than in the SBA and VXA datasets (mean
bias < 0). However, when comparing BIN and SBA datasets for
lactating IMt, higher AMU was reported in the SBA dataset than
in the BIN (mean bias > 0).
Figures 3A–C present a selected example (all drug types)
of AMU metric comparisons between BIN vs. SBA, BIN vs.
VXA, and SBA vs. VXA, respectively. Very few data points
were found in the line of equality (y = 0), thus confirming
discrepancies between datasets. A great variability but no clear
pattern was observed between the datasets. The presence and
extent of potential systematic bias between compared datasets
were evaluated with a regression line (red dotted line in Figure 3)
and related agreement limits. If two dataset metrics are similar,
then the regression line should be coincident with the line of
equality (x = y), i.e., the slope of the regression line should be
equal to one. For most of the comparisons made, the slopes were
significantly different from one, indicating no real agreement
between the methods (Table 3). However, for dry-cow IMt (all
comparisons) and lactating IMt (BIN vs. SBA), the slopes of
the regression lines were not significantly different from one
(Table 2), indicating agreement between the dataset for those
farms where IMt was recorded.
Associations Between Production Type,
Administration Form, and AMU
The associations between total DCDvet/animal/year and
production type (conventional vs. organic production),
observation period, and drug administration form, as estimated
in the linear models, in the VXA dataset are given in Table 3 and
the BIN dataset in Table 4.
VXA Dataset
No difference in AMU was found between production systems
and observation period had no association with AMU. However,
drug administration form did have an impact on the metric in
that injectable drug had the highest AMU metric compared to
the other drug presentations, where intrauterine drugs had the
lowest AMUmetric.
BIN Dataset
Numerical but non-statistical differences were found between
organic and conventional herds, and no difference in AMU was
seen between observation periods. However, drug administration
form affected the AMU metric. Injectable drugs had the highest
metric while lactating IMt the lowest. An interaction between
the production system and drug administration form was found.
Injectable drugs and IMt for lactating cows differed by the
production system, where organic herds had a lower AMUmetric
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FIGURE 3 | Bland–Altman plots of (A) BIN vs. SBA dataset (B) BIN vs. VXA dataset and (C) SBA vs. VXA datasets on a sample of 60 farms in Sweden. (−−−)
Regression line between the measures; (….) Limits of agreement for the regression line; (____) Line of equality (y = 0).
than the conventional herds. However, organic and conventional
herds had similar AMUmetrics for dry-cow IMt.
DISCUSSION
To effectively address the situation of AMU and AMR, herd-
level data are needed. To our knowledge, this is the first study
to provide a full description of AMU regardless of medical
indication and split by production type (i.e., organic and
conventional herds) in a Swedish dairy context.
The BIN method captured more drug use than SBA and
VXA. The first type of discrepancy found was in the number
of herds with corresponding reports of AMU across all datasets.
The lowest percentage of discrepancies was found between SBA
and VXA reports, especially for the injectable forms. Yet, the
highest percentage of discrepancies was found between BIN and
VXA datasets, especially for intramammary tubes for dry-cow
treatments. The second type of discrepancy was in the amount
of AMU reported among datasets. Here, Bland–Altman analyses
indicated an overall trend of AMU underreporting in the SBA
and VXA datasets compared to the reports from the BIN dataset.
In most cases, the limits of agreement were large but not beyond
what would be considered “clinically acceptable” (33), as in most
cases, the disagreement represented <1 treatment course per
animal. Consequently, datasets could be used interchangeably.
However, as large discrepancies were found for intramammary
drug forms, any metrics should take this into account.
A major strength of the BIN dataset is that “overreporting”
of AMU is unlikely. This could occur if farm staff
discarded outdated or unused drugs, or if half-empty
packages/bottles/tubes were reported as fully used. We reduced
that risk by making sure that all recorded packages were
either empty or reported as the amount used if a half-empty
package/bottle was found. In Sweden, the amount of the drug
prescribed and dispensed to a farm or individual should match
the volume/amount necessary to cover the treatment. Any
leftovers must be safely discarded, preventing antimicrobial
hoarding or imprudent handling of waste (34). Adherence to
this could not be confirmed on the visiting farms. Yet, finding
partially used bottles/packages in the BIN might suggest that
staff on-farm indeed discard leftovers as required.
However, when SBA or VXA report higher AMU than in the
BIN, we have little room to know if actual “underreporting” in the
BIN occurred, i.e., if farm staff forgot (intentionally or not) to put
the empty packaging in the BIN. In our study, we could establish
real, yet probably unintentional, underreporting in the BIN for
intrauterine drugs. We found no intrauterine drug packages in
the BIN; however, a few such reports were found in the other
datasets. Upon discussion with veterinary practitioners, it was
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TABLE 3 | Associations between production type and drug administration form [least-square (LS) means, 95% confidence intervals (CI)] on antimicrobial use (obtained
from VXA data) measured as the number of defined courses animal/year (DCDvet/animal/year) and as estimated in a linear mixed model, in a sample of 56 (27 Organic
and 29 Conventional) Swedish dairy herds.
Factor *DCDvet/animal/year
LS mean Low 95% CI High 95% CI P-value
Production type Organic 0.02 0.007 0.040 0.408
Conventional 0.02 0.011 0.051
Drug administration form Intramammary tube (lactating cow) 0.05 0.032 0.087 <0.001
Intramammary tube (dry-cow) 0.06 0.030 0.123
Intrauterine 0.02 0.003 0.058
Parenteral/injectable 0.14 0.106 0.184
*DCDvet/animal/year (i.e., dependent variable) required a Box–Cox transformation for analysis; back-transformed data are presented. Besides production type, only factors significantly
(P < 0.05) associated with the dependent variable were retained in the model and are presented in the table. Bold values indicate the P-value <0.05.
TABLE 4 | Associations between production type and drug administration form [least-square (LS) means, 95% confidence interval (CI)] and antimicrobial use (obtained
from BIN data) measured as the number of defined courses animal/year (DCDvet/animal/year) and as estimated in a linear mixed model, in a sample of 60 (30 organic and
30 conventional) Swedish dairy herds.
Factor *DCDvet/animal/year P-value
LS mean Low 95% CI High 95% CI
Production type Organic 0.08 0.059 0.118 0.067
Conventional 0.13 0.096 0.171
Drug administration form Intramammary tube (lactating cow) 0.04 0.030 0.066 <0.001
Intramammary tube (dry-cow) 0.09 0.065 0.119
Parenteral/injectable 0.25 0.206 0.304
**Interaction: (Production type) ×
(Drug administration form)
Intramammary (lactating cow) Organic 0.03 0.013 0.054 0.033
Conventional 0.07 0.043 0.106
Intramammary (dry cow) Organic 0.09 0.055 0.138 0.970
Conventional 0.09 0.058 0.129
Parenteral/injectable Organic 0.20 0.148 0.264 0.026
Conventional 0.31 0.240 0.404
*DCDvet/animal/year (i.e., dependent variable) required a Box–Cox transformation for analysis; back-transformed data are presented. Besides production type, only factors significantly
(P < 0.05) associated with the dependent variable were retained in the model and are presented in the table.
**For the interaction, P-values of the pairwise comparison between production systems for each drug administration form are presented. Bold and italic values indicate the P-value <0.05.
understood that the few intrauterine treatments that take place on
a farm are performed by the veterinarian on the spot. Hence, the
veterinarian routinely discards the gloves, and drug packaging
used together without the involvement of the staff on-farm, and
the packaging does not reach the bin. This behaviour may also
partially explain the overall trend of BIN underreporting AMU
for intramammary tubes for lactating cows. These treatments can
also be carried out on the spot by the veterinarian, and again, the
discarded containers would not necessarily reach the bin.
Several studies have compared AMU based on drug packaging
collections (i.e., BIN method) against other data sources, mainly
farmers’ reports (14, 16, 35). Similar to our study, the authors
found that the BIN method/dataset outperforms other data
sources. These studies attributed the success of the method to
the convenience for staff in reporting AMU with the simple act
of discarding packages, saving them from the burden of collating
information. In our study, the prescribing veterinarians provided
the data for the compared datasets. So, in essence, SBA and VXA
reflect prescriptions, while BIN captures actual use. Veterinarians
in the research team (KS, NF, and SSL) recognise that AMU
reporting is an administrative burden. Depending on the tools
available, records can be either collated manually (i.e., pen and
paper), scanned and sent to SBA to be uploaded electronically,
or transferred manually into a web portal. Alternatively, records
could be transferred electronically directly to the SBA database.
Transferal could be done on the spot as an individual record or
as a bulk of prescriptions later on. Thus, the ability to correctly
collate the information is highly depending on the clinical
record-keeping. Indeed, upon revision of working datasets ahead
of calculations, many treatment records had to be removed as
not enough details were present to determine if they were AMU.
Poor quality in reporting could explain why some herds failed
to present records in SBA or VXA datasets when treatment was
performed based on what was found in the BIN dataset. Another
explanation could be that the full veterinary prescription was
issued before the study period and hence did not appear in the
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databases. However, the actual use of the drug occurred during
the study period, as shown in the BIN.
Nevertheless, the observed discrepancies are consistently
larger for intramammary forms, primarily when related to dry-
cow treatments (77 to 85% of missing records in either SBA
or VXA datasets compared to BIN). Thus, contrary to what is
expected, some prescriptions do not get reported as required.
In Sweden, current recommendations condemn the storage
of antimicrobials (e.g., hoarding of antimicrobial leftovers).
Moreover, blanket treatments or preventive AMU is not allowed;
selective dry cow therapy is permitted only in individual animals,
and cows will only get treated after a diagnosis is made (36, 37).
Thus, the lack of reports in SBA and VXA datasets compared to
the BIN might be an indication of some practice deviations. If so,
further understanding of the quality, magnitude, and drivers of
this are needed.
Based on our results, it could be said that BIN provided more
information on AMU at herd level for short observation periods.
Yet, it is unsustainable for long periods and challenging to scale
up on a national basis. On the other hand, our study confirms that
SBA and VXA could be used interchangeably. Yet, VXA offers
the advantage of being the only standalone dataset for obtaining
herd-level AMUmetrics in the recommended unit, since time-at-
risk can be calculated, over a long time, and scaled to a national
level. Nonetheless, underreporting of intramammary drug forms
needs to be adequately addressed for SBA and consequently for
VXA. Here, we suggest the application of a biannual screening
of a random selection of herds using the BIN methodology. This
exercise would allow formalizing the monitoring and validation
of results captured by SBA and the VXA dataset.
With a focus on BIN reports, we found that the studied farms
had an average treatment incidence and average course treatment
of 0.43 DDDvet/animal/year and 0.22 DCDvet/animal/year,
respectively. Procaine benzylpenicillin (QJ01CE09) was the
preferred (92%) antimicrobial to be used in the reported
treatment entries, where more than half (56%) were related to
udder problems. This is only the second time in more than 20
years that AMU at herd level is published for dairy cattle in
Sweden (38, 39). Direct comparison with these and work in other
countries where treatment incidences are reported (23, 40, 41) are
constrained mainly by variations in sources of data, calculation
methodology, and study design (12).
Despite the challenge of direct comparisons between studies,
current AMU in Swedish dairy herds is much lower compared
to previous reports for Sweden (6.4 DDDcow/1,000 cow-days for
injectable; 3.45 DDDcow/1,000 cow-days intramammary drugs)
(38). Equally, it is also low in an international comparison of
the median number of doses reported (interquartile range 5.5–
13.6 DDDcow/1,000 cow-days) (40). Moreover, results agree with
latest reports by EMA (42, 43). Such reports use the “population
correction unit” (PCU) based on livestock demographics to
estimate the total weight of the livestock population in each
country to then compare AMU across the EU in mg/PCU. The
report indicates that Sweden is the EU member state with the
lowest AMU and after Iceland and Norway the third lowest
within all European countries (43).
Only 16 ATCvet codes, representing six antimicrobial classes,
were found across the datasets. The list is smaller than that
previously reported in Sweden (39, 44) or found in other
international reports (40). For example, our study found
no reports of macrolides. This use was common 20 years
ago and continues to be so in some countries (40). We
found no ATCvet codes representing antimicrobial groups like
cephalosporins, amphenicols, lincosamides, or pleuromutilins.
Injectable (QJ01CE09, 92% farms) and intramammary penicillins
(QJ51CE09, 32% farms) were the most used antimicrobials
followed by tetracyclines (QJ01AA06, 17% farms), albeit
with a low DDDvet/animal/year value compared to that of
penicillins. Internationally, the most reported antimicrobial
groups in dairy cattle are penicillins, and third-generation
cephalosporins (40) and highest-priority critically important
antibiotic (HPCIA) treatments of mastitis could range from 10
to 80% depending on the veterinary practice (44). In our study,
udder health was also the main reason behind the observed
AMU. Yet, the HPCIA treatments were low, and cephalosporin
use was not recorded at all. HPCIA category 1 includes
macrolides, certain penicillins, and tetracyclines, while category
2 includes ampicillins, aminoglycosides, quinolones, 3rd- and
4th-generation cephalosporins, and polymyxins (e.g., colistin).
Moreover, our study also found large variations of HPCIA
treatment percentages across farms. Yet, that includes many
herds with no HPCIA treatments for category 2. Furthermore,
the HPCIA reports for category 2 were mainly due to the use
of aminoglycosides or quinolones but not to cephalosporins
as in other countries. Sweden has a long-standing history of
strengthening its policy recommendations across the human and
veterinary sectors to reduce the AMR burden (43, 45). The efforts
made have had a definite impact on the reduction as well as the
pattern of AMU (17).
Previous studies comparing organic and conventional dairy
herds under Swedish conditions found a marginal difference in
udder health and reproductive performance, implying equally
good animal health in both systems (46–48). Our study presented
marginal differences between organic and conventional farms. It
should be noted, however, that the small differences are due to
an equally low AMU in conventional Swedish farms. Organic
herds had a small advantage in that they had a lower mortality
and less lameness and mastitis cases. Yet, the bulk milk somatic
cell counts were higher for organic farms. Differences had been
reported elsewhere between organic and conventional herds (23,
24), indicating that organic herds had a substantially lower level
of AMU, but the difference in management between organic and
conventional herds is typically larger outside Sweden (49, 50).
Organic herds had numerically lower treatment incidence
and a lower number of treatment courses regardless of dataset
or treatment form. Yet, at a closer look on the BIN dataset
and DCDvet/animal/year metric, an interaction between the
production system and drug administration form was found.
Organic herds had a significant lower AMU for injectables and
intramammary lactating cow treatment forms. Yet, organic and
conventional farms had a similar AMU for intramammary dry-
cow treatment forms.
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A potential explanation for the AMU difference between
organic and conventional herds for particular drug forms, as
suggested by others (23, 24), could be the underlying marginal
difference in udder health between production systems in
Sweden. Yet, evidence also exists that multiple factors beyond
production type characteristics drive the choice of therapy and
relatedmanagement practices, such as farmers’ and veterinarians’
beliefs and social pressure (51, 52). A qualitative enquiry in the
study herds could not relate any particular AMU perception to
production type. Still, the authors highlight some behavioural
discord among the farmers and veterinarians around udder
treatments (53). This, in combination with our findings of
underreporting of dry-cow intramammary tubes, suggests that
these behaviours are a product of a different set of beliefs
around the treatment of cows at dry-off and the practicalities of
prescription and administration across herds, but this requires
further investigation.
CONCLUSION
We conclude that herd-level assessment of AMU is possible
using reported prescriptions in combination with herd data, such
as in the VXA database, with the caveat that intramammary
drugs may be misrepresented. The BIN methodology offered a
more comprehensive alternative to gain an account of AMU at
herd level. However, as this method is labour- and resource-
demanding, it is difficult to apply routinely at a national scale.
Thus, for Sweden, we suggest the application of the BIN
methodology on a random selection of herds to monitor and
validate results captured by SBA and VXA. We also suggest
improving the understanding and reduction of underreporting
of intramammary drug forms.
This study provides a detailed contemporary account of AMU
in Swedish dairy herds. It confirms the reported low AMU based
on sales data. Moreover, we conclude that AMU differs between
organic and conventional farms for particular drug forms that
may partly be driven by the marginal difference in disease
prevalence. The use and reporting of dry-cow intramammary
drug forms requires further investigation.
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